What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.. 2008.
Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.. 2018.
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis. 9:409-17.. 2009.
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Med. 17:368-72.. 2016.
Virological and clinical outcomes in patients with multi (three)-class drug resistance (MDR). 11th Annual Conference of the British HIV Association, 20-23 April 2005.. 2005.
Viral genotype in subtype C significantly influences plasma viral load. 20th International HIV Dynamics & Evolution Conference, 8-11 May 2013.. 2013.
Viral Genotype in Subtype C Significantly Influences Plasma Viral Load. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013.. 2013.
Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes. 14th International HIV Drug Resistance Workshop, 7-11 June 2005.. 2005.
Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.. 2019.
The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.. 2003.
UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.. 2007.
Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.. 2008.
Trends in transmitted drug resistance to HIV-1 in the UK since 2010. British HIV Association Conference (BHIVA) 2015.. 2015.
Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis. 213:1410-8.. 2016.
Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.. 2011.
Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.. 2012.
Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.. 2014.
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.. 2005.
Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.. 2007.